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Abstract  
 
Introduction: Pharmaceutical expenditure is rising by 16% per annum in China and is now 46% of total 
expenditure. Initiatives to moderate growth include drug pricing regulations and encouraging INN 
prescribing. However, no monitoring of physician prescribing quality and perverse incentives. 
Objectives: Assess changes in ARB utilisation and expenditure as more generics become available; 
compare findings to Europe. Methodology: Observational retrospective study of ARB utilisation and 
expenditure  between 2006 and 2012 in the largest hospital in Chongqing District. Results: Variable 
and low use of generics versus originators with a maximum of 31% among combined single ARBs. 
Lower for Fixed Dose Combinations. Prices typically reduced over time, greatest for generic 
telmisartan (-54%), mirroring price reductions in some European countries. However, no preferential 
increase in prescribing of lower cost generics.  Accumulated savings of 33million CNY for this large 
provider if adopted European practices. Conclusion: considerable opportunities to improve prescribing 
efficiency in China. 
 
Introduction 
 
There is increasing scrutiny over pharmaceutical expenditure across countries with growth rates 
averaging 50% in real terms during the past decade [1,101], driven by well-known factors including 
ageing populations and new premium priced drugs [1-3, 101]. This has resulted in multiple reforms 
across countries. Initiatives for established drugs include measures to enhance the utilisation of low 
cost generics versus originators and single sourced (patented) products in a class or related class 
where all products are seen as essentially therapeutically similar. Classes include the proton pump 
inhibitors (PPIs), statins and renin-angiotensin inhibitor drugs [1,3-13], with the latter including both 
angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).  
 
Savings can be substantial with greater utilisation of generics versus originators and patented 
products in a class without compromising care, with prices of generics as low as 2% to 10% of pre-
patent loss prices in some countries [1,3-8,14-17]. Multifaceted demand-side measures to enhance 
their prescribing include encouraging high International non-proprietary name (INN) prescribing, 
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formularies, prescribing guidance, continuous medical education, quality circles, strengthening of drug 
and therapeutic committees (DTCs), prescribing targets, financial incentives and prescribing 
restrictions [1,3-8,10-13,18,19]. Examples of the impact of multifaceted supply- and demand-side 
measures are included in Table 1. 
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Table 1 ± Influence of multiple supply- and demand-side measures on the utilisation and expenditure 
of PPIs, statins and renin-angiotensin inhibitor drugs among selected European countries [1,3,5-8] 
 
Country Impact of initiatives 
Netherlands x Reimbursed expenditure for the PPIs fell by 58% in 2010 vs. 2000 
despite a 3 fold increase in utilisation 
x Reimbursed expendiure for the statins fell by 14% in 2010 vs. 2000 
despite a 3-fold increase in utilisation 
Sweden x Reimbursed expenditure for the PPIs and statins decreased by 49% and 
39% in 2007 vs. 2001 respectively despite a 53% and 3.2 fold increase 
in their utilisation 
UK (Scotland) x Reimbursed expenditure on PPIs in 2010 was 56% below 2001 levels 
despite a 3 fold increase in utilisation; expenditure would have been 
GB£159million greater in 2010 for a 5.2 million population without such 
measures 
x Reimbursed expenditure on the statins in 2010 was only 7% above 2001 
levels despite a 6.2  fold increase in utilisation; expenditure would have 
been GB£290million greater in 2010 for a 5.2 million population without 
such measures 
x Reimbursed expenditure on the renin-angiotensin inhibitor drugs 
remaining relatively stable between 2001 and 2007 despite a 159% 
incease in utilisation 
 
Considerable savings can also be achieved in low- and middle income countries from switching 
originators to the lowest-priced generic drugs [20-22]. 
 
China has also seen considerable increases in pharmaceutical expenditure, growing at over 16% per 
annum during the past decade [22,23]. This growth has been principally driven by increase insurance 
coverage.  The Chinese government has introduced three different types of health insurance targeting 
different populations, with coverage reaching over 90% of the population by 2011 [24-26]. The 
ultimate goal is universal coverage by 2020 [24-29]. As a result of increased coverage, healthcare 
expenditure increased from 3.5% to 5% of GDP between 1995 and 2010, equating to a ten-fold 
increase in per capita spending from US$21 to 220 [26].   
 
As a result, China has introduced a number of measures in recent years to help moderate this growth 
[22,23,25,26]. The principal measures have concentrated on trying to control pharmaceutical prices 
and expenditure in hospitals. This is because more than 80% of total pharmaceutical consumption is 
currently dispensed in public hospitals in China [22,23,30]. In 2010, pharmaceutical revenues for 
Chinese public hospitals were 405.39billion CNY (approximately US$62.4billion), 46% of total 
healthcare expenditure [22,102], with out-of-pocket payments accounting for 36% of total healthcare 
expenditure [26]. This includes mechanisms to lower the price of drugs [22,23]. For state-priced 
products, the National Development and Reform Commission (NDRC) sets maximum retail prices 
(price caps) including mark-ups; for province- or municipality-priced products, the price management 
department determines the retail prices; and for other products the ex-factory and retail prices are 
determined by the manufacturers [22,26,31,32]. For instance, the NDRC has implemented 28 price 
adjustments between 1997 and 2011 to address potentially high prices for common or expensive 
medicines such as cardiovascular drugs or anticancer drugs [22,33].  
 
Medicines in hospitals are subject to tenders in each province and municipality with each hospital 
pharmacy subsequently having its own product list and prices, e.g. for cardiovascular drugs prices 
have changed four times between 2006 to 2011 in Chongqing Urban District alone [22,33]. Published 
studies have suggested these bidding processes reduced prices of essential medicines by 16.9% 
between 2009 and 2011 [26]. However, there are no pricing policies for generics in China unlike 
measures across Europe which have led to low prices [1,3-8,34]. In addition in the current system, 
hospitals typically use the profits from medicine procurement for their sustainability [31,103], with 
pharmaceutical expenditure in hospitals accounting for between 41.5% to 46% RIKRVSLWDOV¶WRWDO
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income between 2006 and 2010 [22,32,35,36,102]. This is because the financial support of the 
Chinese government to public hospitals declined steadily from approximately 60% of hospital 
revenues in 1980s to 8.2% by 2003. Consequently, hospitals use the revenue from drug procurement 
for their sustainability with a permitted 15% mark-up [26,32]. Even with measures to reduce 
procurement prices, the actual mark-up of medicines in hospitals in 2005 averaged approximately 
42% [32]. There are also inducements for physicians to overprescribe drugs as well as prescribe 
drugs that produce the greatest profit for them and the hospital [22,31]. This situation is exacerbated 
by currently low salaries for physicians in China with many physicians earning 5000 CNY (US$780) a 
month or less [37]. 
 
The lack of policies have resulted in more than 5,000 pharmaceutical manufacturers in China 
producing mainly generics [22,32]. It is envisaged that greater transparency in pharmaceutical pricing 
may lead to further price reductions [26]. However, this remains to be seen. 
 
Demand-side measures in China include the development of an essential medicine list, clinical 
guidance and guidelines [23,26,35,38,103]. However, currently there are no measures among public 
insurers to monitor the quality of prescribing [31,36], with emphasis principally on procurement 
activities. There were reforms in 2007 - WKHµ3UHVFULSWLRQ0DQDJHPHQW2UGLQDQFH¶- specifying that 
prescriptions should be written by INN. However, to date there has been limited enforcement [22,32]. 
As a consequence, physicians tend to write prescriptions with the generic (INN) name and 
simultaneously indicate the brand or manufacturer name; alternatively, drugs are listed with the 
corresponding bUDQGQDPHRUPDQXIDFWXUHULQKRVSLWDOV¶,7V\VWHP>22,27]. This is not helped by 
similar patient co-payments for an originator or generic.  
 
The current incentives as well as limited demand-side measures have resulted in considerable 
irrationality in prescribing despite some measures to improve this [26,31,32]. This is illustrated by 
continued appreciable use of injectable drugs in China as well as considerable prescribing of 
antibiotics [31,39]. 
 
These various initiatives in China translated in a variety of outputs (Box 1) when utilisation and 
expenditure was recently analysed for cardiovascular medicines in the Chongqing Region of China 
[22].  
 
Box 1 ± Findings for cardiovascular medicines in the Chongqing Region in China 2006 to 2011 [22] 
 
x The market share of generics among 12 leading cardiovascular (CV) drugs decreased from 50% 
in the first half of 2006 to 34% by the end of 2011, with the market share of originators increasing 
to 66% by the end of 2011 (DDD based) 
x The market share of originators appreciably increased between 2006 and 2008. Narrower 
fluctuations after this 
x Generic versions were available for all 12 drugs from 2006 
x The price of originators were on average 63% higher than generic prices in 2011 
x Prices of generics for the 12 CV drugs varied from 66% to 98% price of the originator in 2011 
x There was potential for considerable savings with greater use of generics if this could be 
engineered alongside obtaining lower prices where possible 
 
We would like to build on these findings looking specifically at angiotensin receptor blockers (ARBs). 
The reasons for this are included in Box 2. 
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Box 2 ± Rationale for the current study researching ARBs in China [3,10,11,14,15,18,22,32,41-43,55-
57,106] 
 
x Ischaemic heart disease and cerebrovascular disease are now among the leading causes of 
death in China 
x Previous studies have shown appreciable price reductions for generics; however, other studies 
have shown less of a difference 
x Generic losartan recently became available in Western Europe with all angiotensin receptor 
blockers (ARBs) seen as essentially similar at appropriate doses 
x There was considerable variation in demand-side measures among Western European countries 
to encourage the prescribing of losartan once generics became available, which has resulted in 
appreciable differences in losartan utilisation post generics without compromising care. There 
were also appreciable differences in generic losartan prices. Consequently, providing an 
opportunity to compare the findings with China  
x Between 2006 and 2012, some generic ARBs alone or in fixed dose combinations (FDCs) were 
included in hospital lists in China providing opportunities to further evaluate generic penetration 
rates and savings building on Box 1  
 
Consequently, the principal objectives of this study are to assess changes in ARB utilisation in China 
as more generic ARBs are incorporated into hospital procurement lists, which includes assessing 
changes in the utilisation of originator versus generic ARBs over time; similarly ARB Fixed Dose 
Combinations (FDCs). Secondly, assess changes in ARB and ARB FDC expenditure over time as 
well as for generic and originator ARBs and ARB FDCs. This includes price reductions over time  
 
We will subsequently compare the findings with Western European countries with China striving for 
universal coverage, which is routine among Western European countries. This will provide a basis for 
suggesting potential future reforms that have been successful in Europe for the authorities in China to 
consider to achieve their aims without further growth at over 16% per annum. 
 
We would expect to see greater prescribing of originators than generics building on our earlier 
findings (Box 1). In addition, variable and sometimes limited price reductions for generics versus 
originators and versus pre-generic inclusion prices. We expect price reductions to be less than those 
seen among some Western European countries for high volume generics including losartan (Box 1). 
This is despite multiple generic ARBs being available in China (Table 2) [102]. 
 
Table 2 - Registered number of approvals for production of generic angiotensin receptor blockerss in 
China in October 2013 [107] 
 
ARBs Losartan Valsartan Irbesartan Telmisartan Candesartan 
Registered numbers of 
approval 
34 43 41 117 32 
 
Methodology 
 
This was an observational retrospective study of prescriptions dispensed over a seven year period 
between 2006 and 2012 [40]. This includes the time period of the previous study (Box 1). This 
methodology was chosen since multiple supply- and demand-side measures have been introduced 
during this period in China making it difficult to perform an interrupted time series analysis. In addition, 
there have been multiple changes to the procurement of single and ARB FDCs over time (Table 3). 
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Table 3 ± Procurement of single ARBs and ARB fixed-dose combinations (FDCs) in the Chongqing 
District from 2006 to 2012 
 
ARB single Date originator available Date when generics first part of 
hospital procurement 
Candesartan Not available Available in 2006 
Irbesartan 2006 2007 (October) 
Losartan 2006 2012 (March) 
Telmisartan 2006 Available in 2006 
Valsartan 2006 Available in 2006 
ARB FDCs   
Irbesartan FDC 2006 2008 (March) 
Losartan FDC 2006 2010 (May) 
Valsartan FDC 2006 Not available 
NB Generic ARBs and FDCs may be available in China during previous years. However, not included in the 
procurement process in view of the considerable data that must be provided as part of tendering 
 
Typically for these types of drug utilisation analysis, data is obtained from health authority, health 
insurance or pharmacy databases [5-8,10,11,15,41-43]. However in China, most drug utilisation 
studies are performed with data from hospitals as they incorporate both inpatient and outpatient data 
[22,44]. In addition, as mentioned, they account for 80% of total drugs currently dispensed in China 
[22]. This is in view of the convenience of hospital dispensing, physician recommendations, possibility 
of nonstandardized prescriptions and greater assurance of pharmaceutical quality in hospitals [32]. 
The quality of pharmaceuticals in hospitals is enhanced by strict quality control as part of the 
tendering process [32]. This builds on reforms to improve the manufacturing standards of generic 
drugs in China implemented from 2000 onwards [26], e.g. in 2009 all medicines on the Chinese 
Essential Medicines List (EML) were required to undergo quality sampling and testing at the provincial 
level at least annually and at the central level at least every three years to be considered for 
procurement [26].  
 
Consequently, hospital procurement data is currently the optimal source of drug utilisation data in 
China. Accurate data on hospital tendering and procurement is especially important for this type of 
analysis given the profit hospitals make from medicines [31,32]. This data is not always available from 
some commercial sources, which just provide maximum retail price data [23]. Hospital procurement 
prices are also not always captured in health insurance data. In addition, hospitals may procure 
medicines that are not currently reimbursed. As a result, further reducing the utility of health insurance 
data as a data source for comprehensive drug utilisation studies in China. 
 
&KRQJTLQJLVDPXQLFLSDOLW\GLUHFWO\XQGHU&KLQD¶VFHQWUDOJRYHUQPHQWZLWKDWRWDOSRSXlation of 28.8 
million people (2010 census). In the urban district in Chongqing City, the main public general hospitals 
include three hospitals affiliated to the Third Military Medical University, two hospitals affiliated to 
Chongqing Medical University, and 10 municipal hospitals. Every hospital may include different 
generic drugs, but with the same originator equivalents as part of the tendering process to obtain 
good prices [22]. However, in view of the complexity of the procurement process only the largest 
hospitals tend to have a comprehensive range of products available for prescribing.  
 
In view of these factors, we chose the largest hospital in Chongqing District to conduct our study. This 
is because it is one of the largest hospitals in Southwest China, has a wide range of medicines 
available for prescribing, can provide comprehensive datasets on both utilisation and expenditure and 
is a typical health provider to the public. The dataset was obtained from the magazine company of 
China Pharmacy. The company is located in Chongqing and is able to collect detailed information 
from large hospitals in southwest China through co-operation with public hospitals. The data contains 
all individual drug information including product names, purchase dates, dosage forms, specifications, 
manufacturers, unit prices and volumes. This is an authoritative source for drug utilisation statistics in 
China, which is regularly audited. We used a similar approach in previous studies [22].  
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7KH&KLQHVHFXUUHQF\5HQPLQEL³yuan´&1< was used to determine expenditure and expenditure/ 
DDD for ARBs and ARB FDCs over time. These were not adjusted for inflation or deflation during this 
period as we wanted to compute actual changes over time as a result of the tendering process. This 
is because most health authorities typically decrease prices when budgets are being exceeded 
[45,46] making adjustments based on factors such as retail price indexes or purchasing price parity 
difficult to justify when reviewing pharmaceutical prices. This is in line with previous studies [5-
8,10,11,41,42]. We have also not converted CNY data to either US$ or Euros during the course of the 
study as we did not want the pricing data influenced by currency fluctuations especially during the 
recent financial crises in Europe and the US. Originator ARBs are referred to as products currently or 
previously possessing intellectual property (patent), which are either from multinational companies or 
manufactured by joint ventures in China founded by multinational pharmaceutical companies. Generic 
drugs are domestic products produced by Chinese enterprises with local investment, including state-
owned and private enterprises. There is strong competition with a number of manufacturers (Table 2).  
 
Five single ARBs and three ARB FDCs were available in the target hospital (ATC C09CA01 to 09, 
C09DA01 to 05, C09DX01 to 03 [104]) between 2006 and 2012 (Table 3). Utilisation was measured in 
WHUPVRI'HILQHG'DLO\'RVHZLWK'''VGHILQHGDVµthe average maintenance dose of a drug when 
used in its major indication in adults¶ZLWKWKLVPHDVXUHUHFRJQLVHGDVWKHLQWHUQDWLRQDOVWDQGDUGWR
assess utilisation patterns within and between countries [105]. The data was subsequently 
aggregated for analysis. 2011 DDDs were used in line with international guidance [47,48,105]. The 
WHO methodology used to calculate the DDDs for combination products, based on the principle of 
counting this as one dose [105]. 
 
We subsequently divided ARBs into single and ARB FDCs as ARB FDC utilisation varied 
considerably among Western European countries, ranging from 2% to 3% of ARB/ losartan utilisation 
in the UK to 50% in Austria [10,41-43]. This was due to issues such as the extent of increased 
compliance in practice, economics as well as access to diuretics. 
 
A narrative review of published studies to appraise the utilisation and expenditure of ARBs among 
selected Western European countries was undertaken by one of the co-authors (BBG). The studies 
selected were based on multiple publications that the co-authors were involved with providing 
exemplars of potential measures the authorities in China could consider as they move towards 
universal coverage. 
 
Results 
 
Utilisation 
 
There was an appreciable increase in the prescribing of ARBs alone or as FDCs, rising 12 fold from 
just over 209,000 DDDs in 2006 to 2.45million in 2012 across all products (Figure 1). 
 
 8 
Accepted, peer-reviewed author manuscript of the following article: Zeng, W., Gustafsson, L. L., Bennie, M., Finlayson, A. E., & Godman, B. 
(2015). Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history. Expert Review of 
Pharmacoeconomics and Outcomes Research, 15(1), 157-169. 10.1586/14737167.2015.963557 
© Informa Healthcare 
Figure 1 ± Utilisation of single and FDC ARBs (DDDs) between 2006 and 2012 in the Chongqing 
District from 2006 to 2012 
 
 
NB. FDCs = Fixed Dose Combinations. 
 
The greatest increase in utilisation was seen for both telmisartan and valsartan among the single 
ARBs and for irbesartan among the FDCs (Figure 1, Table 4). However, there was variable use of 
generic versus originator ARBs, i.e. there was a rapid increase in the use of generic irbesartan 
peaking at 44% of total irbesartan in 2009 before declining to 33%. A similar pattern was seen for 
telmisartan peaking at 40% of total telmisartan utilisation in 2011 before falling to 30% in 2012. There 
was also an increase in generic candesartan in 2012 vs. 2006, although this varied by year (Figure 1) 
resulting in its share of total single ARBs falling from 20% in 2006 to between 2% to 4% between 
2010 and 2012 (Figure 1, Table 4).  
 
The variable use of generics among the single ARBs led to their overall utilisation increasing from 
24% of total single ARBs in 2006 to 31% in 2008 before falling to between 22% and 24% between 
2010 and 2012 (Table 4). This was despite increasing availability of generic ARBs (Tables 2 and 3). 
 
There was also a 21.5 fold increase in ARB FDC utilisation between 2006 and 2012, greatest for 
irbesartan FDC (108 fold) (Figure 1, Table 4). As a result, there was increasing use of ARB FDCs as a 
% of total ARBs, rising from 11% in 2006 to stabilising at 19% to 20% between 2010 and 2012. There 
was also increasing use of generic ARB FDCs reaching 19% of total ARB FDCs in 2012. 
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Table 4 ± Consolidated utilisation of single and FDC ARBs (in DDDs) including generics and 
originators in the Chongqing District from 2006 to 2012 
 
Single ARBs 2006 2007 2008 2009 2010 2011 2012
Degree of 
change
Candersartan Generic 36960 62580 70560 60480 30880 52400 83190 2.3
Losartan 
Losartan - Originator 61740 114597 182700 252210 414400 379400 431340
Losartan - Generic 64400
Losartan - Total 61740 114597 182700 252210 414400 379400 495740 8.0
% Generic 13
Irbesartan
/ƌďĞƐĂƌƚĂŶ ?KƌŝŐŝŶĂƚŽƌ 46550 80500 88802 143640 230440 239400 302400
Irbesartan - Generic 4200 67800 111600 154410 118800 150000
/ƌďĞƐĂƌƚĂŶ ?dŽƚĂů 46550 84700 156602 255240 384850 358200 452400 10
% Generic 5 43 44 40 33 33
Telmisartan
dĞůŵŝƐĂƌƚĂŶ ?KƌŝŐŝŶĂƚŽƌ 22148 50218 117600 125020 162400 207872 366800
dĞůŵŝƐĂƌƚĂŶ ?'ĞŶĞƌŝĐ 1764 21000 74368 78400 106400 137200 156450
dĞůŵŝƐĂƌƚĂŶ ?dŽƚĂů 23912 71218 191968 203420 268800 345072 523250 22
% Generic 7 29 39 39 40 40 30
Valsartan
sĂůƐĂƌƚĂŶ ?KƌŝŐŝŶĂƚŽƌ 12362 29750 100863 147210 168000 280980 412160
sĂůƐĂƌƚĂŶ ?'ĞŶĞƌŝĐ 5698 8400 2800 7350 11200 9100 12075
sĂůƐĂƌƚĂŶ ?dŽƚĂů 18060 38150 103663 154560 179200 290080 424235 23.5
% Generic 32 22 3 5 6 3 3
Combined total
Total Generic Single ARBs 44422 96180 215528 257830 302890 317500 466115 10.5
Total Single ARBs 187222 371245 705493 925910 1278130 1425152 1978815 11
% Generic 24 26 31 28 24 22 23
FDC ARBs
Irbesartan FDCs
/ƌďĞƐĂƌƚĂŶ& ?KƌŝŐŝŶĂƚŽƌ 2800 27314 58100 92960 133560 166320 223440
/ƌďĞƐĂƌƚĂŶ& ?'ĞŶĞƌŝĐ 13510 23100 44520 50400 77840
/ƌďĞƐĂƌƚĂŶ& ?dŽƚĂů 2800 27314 71610 116060 178080 216720 301280 108
% Generic FDC 19 20 25 23 26
Losartan FDCs
>ŽƐĂƌƚĂŶ& ?KƌŝŐŝŶĂƚŽƌ 19306 38850 78400 79100 119490 121800 160370
>ŽƐĂƌƚĂŶ& ?'ĞŶĞƌŝĐ 3500 9800 12880
>ŽƐĂƌƚĂŶ& ?dŽƚĂů 19306 38850 78400 79100 122990 131600 173250 9
% Generic FDC 3 7 7
sĂůƐĂƌƚĂŶ& ?ŽƌŝŐŝŶĂƚŽƌ 350 1960
Combined total
Total generic FDCs 13510 23100 48020 60200 90720
Total FDCs 22106 66164 150360 197120 301070 348320 474530 21.5
% Generic FDCs 9 12 16 17 19
All ARBs
Total ARBs (all) 209328 437409 855853 1123030 1579200 1773472 2453345 12
Total single ARBs (%) 89 85 82 82 81 80 81  
NB. FDCs = Fixed Dose Combinations. % Single ARBs = % single ARBs vs. total ARBs  
 
Expenditure 
 
Total ARB expenditure (single and FDCs) also increased appreciably, rising from just over 1million 
CNY in 2006 to 9.87million CNY in 2012 (Figure 2).  
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Figure 2 ± Total expenditure of ARBs (single and FDCs) 2006 to 2012 in 5HQPLQEL³yuan´&1< in 
the Chongqing District from 2006 to 2012 
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NB. FDCs = Fixed Dose Combinations. 
 
The lower increase in total expenditure (9.8 fold) versus utilisation (12 fold) was helped by reducing 
expenditure/ DDD for the various ARBs (Table 5). However, there was only a marginal decrease for 
single originator ARBs combined at 7% in 2012 vs. 2006 compared with a 44% procured price 
reduction for generics. This resulted in an overall 17% price reduction for single ARBs combined 
between 2006 and 2012 (Table 5).  
 
There was also considerable variation in procured price reductions for individual generic ARBs over 
the course of the study. These ranged from 22% for generic valsartan to 39% for candesartan and 
54% for telmisartan. Expenditure/ DDD for generic irbesartan was 33% below pre-inclusion prices in 
2012 (Table 5). There were also variable differences in procured prices of generic versus originator 
single ARBs. This was greatest for valsartan reaching 59% in 2012. This compares to a maximum of 
32% for irbesartan in 2012, with the difference steadily growing over time. There was considerable 
variation for telmisartan, ranging from a 31% increase in 2006 to a 39% decrease in 2012, with again 
a greater decrease in recent years. 
 
There was a greater procured price reduction for combined originator FDCs at 21% during the study 
period versus single originator ARBs at 7%. Expenditure/ DDD for generic FDCs combined reduced 
by 49% in 2012 vs. combined originator FDC prices in 2006 (Table 5).  
 
One reason for increased utilisation of irbesartan FDCs in recent years (Table 4) could be the limited 
procured price differential between originator and generic single drugs and corresponding FDCs in 
2011 and 2012, with a maximum 18% difference between originator single and FDCs in 2007. 
However, there were no appreciable price differences between generic single and FDC irbesartan 
between 2008 and 2012. In fact in 2011 expenditure/ DDD for the generic FDC irbesartan was lower 
than single irbesartan (Table 5). 
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Table 5 ± Expenditure/ DDD for single ARBs (generic and originator) and FDC ARBs (generic and 
originator) in the Chongqing District from 2006 to 2012 
 
ARB single 2006 2007 2008 2009 2010 2011 2012
% change 
2012 vs. 2006
% change in 
2012 vs. pre-
patent loss 
Candesartan (generic) 5.397 4.492 4.310 4.310 4.294 3.313 3.315 -39
/ƌďĞƐĂƌƚĂŶ ?KƌŝŐŝŶĂƚŽƌ 4.562 4.489 4.466 4.466 4.466 4.466 4.466 -2 -2
/ƌďĞƐĂƌƚĂŶ ?'ĞŶĞƌŝĐ 3.827 3.825 3.825 3.825 3.212 3.057 -33
Irbesartan % Difference -15 -14 -14 -14 -28 -32
Losartan (Originator) 4.865 4.719 4.705 4.546 4.552 4.423 4.169 -14 -6
Losartan (Generic) 4.720 7
% Losartan Difference 13
dĞůŵŝƐĂƌƚĂŶ ?KƌŝŐŝŶĂƚŽƌ 2.478 2.480 2.439 2.439 2.439 2.439 2.439 -2
dĞůŵŝƐĂƌƚĂŶ ?'ĞŶĞƌŝĐ 3.239 2.566 2.516 2.516 2.516 1.743 1.479 -54
Telmisartan % Difference 31 3 3 3 3 -29 -39
sĂůƐĂƌƚĂŶ ?KƌŝŐŝŶĂƚŽƌ 6.247 6.232 6.111 6.111 6.111 5.761 5.585 -11
sĂůƐĂƌƚĂŶ ?'ĞŶĞƌŝĐ 2.925 2.834 2.834 2.834 2.630 2.412 2.286 -22
Valsartan % Difference -53 -55 -54 -54 -57 -58 -59
dŽƚĂů^ŝŶŐůĞZƐ ?ŽƌŝŐŝŶĂƚŽƌ 4.516 4.407 4.407 4.480 4.449 4.399 4.195 -7
dŽƚĂůƐŝŶŐůĞZƐ ?'ĞŶĞƌŝĐ 4.994 3.898 3.519 3.512 3.369 2.571 2.783 -44
Total single ARBs 4.629 4.275 4.136 4.210 4.193 3.992 3.862 -17
ARB FDCs
/ƌďĞƐĂƌƚĂŶ& ?KƌŝŐŝŶĂƚŽƌ 5.196 5.296 5.196 5.196 5.184 4.471 4.471 -14 -16
/ƌďĞƐĂƌƚĂŶ& ?'ĞŶĞƌŝĐ 3.913 3.913 3.913 3.194 3.114 -41
% Irbesartan Difference -25 -25 -25 -29 -30
>ŽƐĂƌƚĂŶ& ?KƌŝŐŝŶĂƚŽƌ 6.548 6.577 6.507 6.507 6.476 5.892 5.863 -10 -10
>ŽƐĂƌƚĂŶ& ?'ĞŶĞƌŝĐ 3.897 3.897 3.897 -40
% Losartan FDC Difference -40 -34 -34
sĂůƐĂƌƚĂŶ& ?ŽƌŝŐŝŶĂƚŽƌ 6.963 6.963
Total generic FDCs 3.913 3.913 3.912 3.309 3.225 -49
Total originator FDCs 6.377 6.048 5.952 5.812 5.794 5.072 5.053 -21  
NB. FDCs = Fixed Dose Combinations.  Pre-patent loss = pre-procurement of generics (although may have been 
available for procurement before this) 
 
There were considerable differences in the utilisation of losartan among selected Western European 
countries post generics (Table 6). Similarly for price reductions for generic losartan over time versus 
pre-patent loss prices. 
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Table 6 ± Differences in demand-side measures among selected European countries to enhance 
losartan utilisation post generics and their impact [10,11,39,41,55,56] 
 
Country Summary demand-side measures % losartan 
utilisation 
time 0 
% losartan 
utilisation 
at the 
study end  
% price 
generic 
losartan 
vs. 
originator 
Austria x Prescribing restrictions removed for losartan 
but not the other ARBs 
x Potential sanctions for physician abuse 
including financial penalties 
10% 17%* 17% 
 
Belgium x Prescribing restrictions removed for losartan 
but not for patented ARBs 
x Patented ARBs still needed prior approval 
from health insurers - otherwise a 100% co-
payment 
20% 24%* 54% 
Denmark x Delisting of all other ARBs other than 
losartan from the reimbursed list 
x Patients can be prescribed another ARB. 
However the prescription must be justified  
and accepted ± otherwise 100% co-payment 
35% 93%* 12% (total 
losartan) 
Ireland x No specific activities undertaken  24% 23% 56% 
Scotland x No specific activities undertaken  
x However, losartan 99% generic due to high 
voluntary INN prescribing 
33% 34%** 12% 
Spain 
(Catalonia) 
x No specific activities undertaken 17% 19% 32% 
Sweden x Multiple demand-side measures including 
formularies recommending losartan; 
academic detailing; prescribing targets for % 
losartan, therapeutic switching programmes 
among some Counties (regions)  and 
physician or practice based financial 
incentive schemes  
x Ongoing compulsory generic substitution in 
pharmacies (resulting in losartan 97% 
generic)  
x From May 2011, prescribing restrictions lifted 
for losartan but not the other ARBs 
27% 39%* 10% 
NB. Utilisation measured in DDDs and % refers to % losartan vs. other single ARBs. Time 0 = time when generic 
losartan first reimbursed. Study end varied from 13 to 30 months post generic losartan. % price generic losartan 
= % price by the study end vs. the pre-patent loss price of the originator (typically reimbursed expenditure/ DDD). 
ARBs = angiotensin receptor blockers. * = statistically significant difference. ** Not statistically significant 
 
A similar situation was seen in one Primary Care Organisation in the UK to that in Scotland and 
Sweden [10,15,43]. Initially, there was no immediate change in losartan utilisation following generics 
with no specific demand-side measures similar to Scotland. However, subsequent multiple demand-
side measures similar to Sweden (Table 6) resulted in losartan increasing from 26% of all single 
ARBs to 65% 7 months later, leading to appreciable savings [15]. 
 
Discussion 
 
We will initially discuss utilisation and expenditure patterns in the Chongqing District before comparing 
the findings with Western European countries (Table 6) as a basis for suggesting future initiatives in 
the region. As expected, there was variable utilisation of originator ARBs as more multiple sourced 
ARBs become available (Tables 3 and 4).  
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However, there appeared to be variable rationality in prescribing with the utilisation of both valsartan 
(most expensive originator) and telmisartan (cheapest originator varying between 56% to 60% lower 
than valsartan between 2010 and 2012) growing substantially during the study period with telmisartan 
accounting for 26% of total single ARBs by 2012 and valsartan 21% (Tables 4 and 5). In addition, the 
utilisation of both candesartan and irbesartan, with the prices of originators between valsartan and 
telmisartan, decreased as a percentage of total single ACEIs during the study period (Tables 4 and 
5).  This irrationality continued with generic ARBs with their utilisation reaching a maximum 28% to 
31% of total single ARBs between 2008 and 2009 before falling to 22% to 24% between 2010 and 
2012 (Table 4), with the price difference between the most expensive originator ARB and cheapest 
generic ARB being 59% in 2010 and 74% in 2012 (Table 5). 
.  
This was different for the FDCs. The combined utilisation of generic FDCs rose steadily throughout 
the study, reaching 19% of total ARB FDCs in 2012 (Table 4). Overall, there was a steady increase in 
FDC utilisation, stabilising at 19% to 20% of total ARBs by 2012 (Figure 1, Table 4). This may be 
facilitated by similar prices for single ARBs and FDCs in some cases as seen with irbesartan (Table 
5). However, it is difficult to comment further without specific research. 
 
The various findings appear to confirm continued irrationality in the prescribing of single ARBs, 
mirroring the findings in other classes and with injectables versus oral drugs [22,31,39,49].  Having 
said this, there appears to be progress with obtaining reasonable price reductions for generics versus 
originators in hospitals in China, building on the many supply-side measures and initiatives described 
earlier. This can be seen with procured price reductions for generic single ARBs versus pre-patent 
loss prices (Table 5) matching some of those seen among some Western European countries (Table 
6). This can also be seen with a 54% reduction in the procured price of generic telmisartan over time 
as well as a 33% to 41% price reduction for irbesartan generics and irbesartan FDCs respectively in 
2012 vs. pre-patent loss prices. We believe the procured price reduction for generic temisartan would 
have been greater if we were able to obtain earlier procured prices. This matched some of the price 
reductions seen with the earlier research (Box 2).  
 
However, we believe there are still opportunities for further price reductions to match those for generic 
losartan in Denmark, Sweden and the UK (Scotland) (Table 6). Potential initiatives could include new 
regulations encouraging greater transparency in the pricing of generics. In the UK, this resulted in the 
prices of generics falling by 32.4% in the first year of the introduction and generic simvastatin just 3% 
of pre-patent loss prices in recent years [1,3,7,34].  
 
There are also considerable opportunities to enhance the utilisation of low cost generics versus 
originators especially following the reforms to improve manufacturing standards for generics [26,32]. 
However, it is likely future demand-side measures will have only limited success unless the perverse 
incentives for physicians and hospitals are substantially reduced, which currently encourage the 
prescribing and dispensing of premium priced originators versus generics (Tables 4 and 5). Once 
addressed, potential demand-side measures could include greater enforcement of INN prescribing. 
Voluntary INN prescribing in Scotland, achieved through a variety of demand side measures, 
including physician training in medical schools and follow-up in ambulatory care, resulted in INN 
prescribing rates of 98% to 99% of total utilisation among a range of classes and drugs [34].  There 
are also potential measures to enhance the rational use of medicines building on the essential 
medicine list concept [26,31]. This includes encouraging the preferential prescribing of low cost 
multiple sourced drugs versus more expensive originators. Restricting prescribing choices will 
enhance physician familiarity with the medicines they prescribe. As a result, reduce potential adverse 
drug reactions and drug: drug interactions as well as strengthening the procurement process. This 
was the philosophy behind the generation of the Wise List in the Stockholm Healthcare Region, which 
contains approximately 200 drugs including first and second line choices covering most of the needs 
in ambulatory care [4,19,50]. An additional 100 drugs are included in a separate list reserved for 
common needs in specialist in- and out-patient care. High adherence rates at 80 to 90%% to the 
voluntary Wise List are enhanced by the involvement of prescribers in the selection process, a 
comprehensive communication programme including a separate list for both patients and physicians, 
physician trust in the guidance as well as regular feedback [4, 19,50]. Increased adherence also 
reduces costs [4,16,19]. There are similar examples in Spain and Scotland [7,34,50]. 
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Such a system could be introduced in Chongqing District along with continuous medical education 
and strengthening of hospital DTCs, providing an exemplar to other provinces and municipalities 
throughout China as they tackle similar issues. However, this will need strong leadership including 
instigating quality measures and involving prescribers to attain success [51]. Restricting the formulary 
to just one ARB and one ARB FDC based on the cheapest ARB (telmisartan for single ARBs and 
irbesartan for FDCs) would have saved an accumulated17million CNY for this leading hospital alone 
between 2006 and 2012. This is in line with Denmark as well as Sweden and NHS Bury (UK) with 
their active switching policies along with other measures (Table 6) without affecting care 
[10,11,14,15,17]. Accumulated savings increase to 33million CNY with generic pricing similar to 
Scotland (Table 6).   
 
We believe these findings are generalizable to other classes and other hospitals in China given our 
methodology as well as the current regulations and tendering system in China. However, this remains 
to be seen and is a recognised weakness of our approach. Another weakness of our paper is that we 
have not accessed patient records to see if the changes in ARB utilisation patterns affect subsequent 
quality of care. However, we do not believe this will be the case based on the findings that all ARBs 
are seen as essentially similar in clinical practice at appropriate doses [14-17]. 
 
Never-the-less, we believe our findings that ongoing reforms in China are leading to price reductions, 
mirroring those seen in other countries, are justified. There is still though a considerable opportunity 
for the hospitals and authorities in China to achieve further substantial price reductions for generics as 
well as enhance their use. Both will be needed if China is to achieve its aim of universal coverage 
without further substantial increases in pharmaceutical expenditure. We believe this can be achieved 
through active formulary management and the increase in physician continuous medical education 
including benchmarking physician prescribing similar to practices seen among Western European 
countries. However for long term sustainability, there must be changes in the remuneration system for 
hospitals and physicians. This builds on current contracting initiatives in some hospitals and regions 
[52]. There must also be regulations and laws to reduce unethical practices including rebate practices 
similar to recent regulations and laws in Europe, Korea and the US [6,53,54].   
 
In conclusion, we believe we have demonstrated that there is still considerable irrationality in 
prescribing in China despite recent measures and that there are considerable opportunities to save 
costs without compromising care. We believe China can achieve this by learning from exemplars 
among Western European countries and successfully implementing these.  However, this needs 
changes in the remuneration system to hospitals and physicians. Without such measures, China is 
unlikely to attain its goal of universal insurance coverage by 2020. 
  
Key issues 
 
x Pharmaceutical expenditure rose steadily at over 16% per annum during the past decade with 
medicines accounting for 46% of total expenditure in 2010. 80% of medicines are currently 
dispensed in hospitals 
x Physicians and hospitals currently use the prescribing and procurement of medicines to enhance 
their income, with the average mark-up on medicines in hospitals at 42% in 2005. This has 
resulted in considerable irrationality in prescribing despite initiatives such as Essential Medicine 
Lists 
x This irrationality was also seen when the utilisation of ARBs and their expenditure was examined 
in the largest hospital in Chongqing District of China and one of the largest hospitals in South 
West China 
x The utilisation of ARBs increased substantially between 2006 and 2012. However, the utilisation 
patterns for different originator ARBs was variable and did not reflect their procured prices. There 
was also typically low utilisation of cheaper generics versus originators 
x The reduction in the procured prices for generics over time were similar to those seen among 
some Western European countries. However, there are still considerable opportunities to further 
lower prices of generics as well as enhance their utilisation vs. originators 
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x Introducing supply- and demand-side measures in China similar to Western European countries 
would enhance the potential for China to achieve its desired goal of universal coverage by 2020. 
However, this will need substantial changes to the remuneration system for physicians and 
hospitals to achieve this 
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